Shanghai Sunmi Technology Co., Ltd. (Ticker: 6810 HK) is a Chinese company specializing in Business Internet of Things solutions and smart commercial equipment, such as self checkout terminals. Shanghai Sunmi Technology plans to list on the Hong Kong Stock Exchange on April 29, 2026, planning to offer 42.63 million shares at a price of HKD 24.86, raising HKD 1.06 billion (USD 135.33 million). Based on the offering details, the implied market capitalization is expected to reach USD 965.30 million.

According to the prospectus, the company is a leading global Android-based BIoT solution provider. It integrates hardware, software, and data insights to streamline business operations such as payments, order fulfillment, and inventory management, powered by its proprietary SUNMI OS. The corporate structure for the listing involves an H Share issuance.

As reported in the published terms, Shanghai Sunmi Technology plans to use the IPO proceeds primarily for research and development and product capacity enhancements. Additional funds will reportedly be allocated toward brand promotion, business development, working capital, and strategic acquisitions. The joint sponsors and underwriters managing the offering include CITIC Securities, Deutsche Bank, and ABCI Capital.

Silver Bow Mining Corp. (Ticker: SBMT US) is a Canadian-domiciled minerals exploration company focusing on silver, zinc, gold, lead, and copper targets in Montana, USA. Silver Bow Mining plans to list on the NYSE American exchange on April 29, 2026, planning to offer 4.35 million shares at a price range of $10.00 to $13.00, raising $50.03 million. The company is expected to have a market capitalization of $329.66 million at the IPO.

According to the prospectus, Silver Bow Mining plans to use the IPO proceeds to continue the exploration of its primary property, the Rainbow Block, to move towards the completion of a feasibility study. The company, which is in the exploration stage with no history of operations or revenue, owns approximately 3,347 acres in patented mineral claims in Silver Bow County.

According to published terms, the company recently revised its IPO structure, increasing the number of shares offered from an original 3.7 million while lowering the price range from the initial $12.00 to $15.00. Cantor Fitzgerald, Research Capital USA, Joseph Gunnar, Roth Capital, and R.F. Lafferty & Co. will act as joint bookrunners.

Pershing Square Inc. (Ticker: PS US) is a United States-based company specializing in alternative asset management. Pershing Square plans to list on the NYSE on April 29, 2026, planning to offer 100 million shares at a price of $50.00 per share, raising an estimated $5 billion. The company has a reported market capitalization of $20 billion.

According to sources, prior to the IPO, the company will undergo a statutory conversion from a Delaware limited partnership, Pershing Square Holdco, L.P., into a Nevada corporation. Reportedly, this IPO is a component of a combined offering alongside the IPO of Pershing Square USA, Ltd. (PSUS), a registered non-diversified, closed-end investment company. The firm expects to deliver 20 shares of Pershing Square Inc. common stock for every 100 PSUS shares purchased by initial investors in the PSUS offering for no additional consideration.

As of December 31, 2025, the firm reportedly held approximately $30.7 billion in total assets under management. The offering is being managed by a joint team that includes Citigroup, UBS Investment Bank, BofA Securities, Jefferies, and Wells Fargo Securities.

Avalyn Pharma (Ticker: AVLN US) is a US-based clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment of serious, rare respiratory diseases. Avalyn Pharma plans to list on the NASDAQ on April 30, 2026, planning to offer 11.8 million shares at a price range of $16.00 to $18.00, raising around $200 million. The company is expected to achieve a market capitalization of $628 million at the IPO.

According to the prospectus, the company's clinical pipeline is heavily focused on treating pulmonary fibrosis by delivering optimized inhaled formulations of approved oral medicines directly to the lungs, aiming to enhance efficacy and minimize systemic side effects. Its most advanced clinical candidates, AP01 and AP02, are inhaled formulations of pirfenidone and nintedanib targeting progressive and idiopathic pulmonary fibrosis. As reported in the prospectus, the pre-revenue company recorded a net loss of $85.2 million for the year ended December 31, 2025. Morgan Stanley, Jefferies, Evercore ISI, and Guggenheim Securities are serving as the joint managers for the offering.

Seaport Therapeutics, Inc. (Ticker: SPTX US) is a US-registered clinical-stage therapeutics company focused on developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Seaport Therapeutics plans to list on the NASDAQ exchange following its scheduled pricing on April 30, 2026. The company is planning to offer 11,800,000 primary shares at an estimated price range of $16.00 to $18.00 per share, targeting an overall IPO offer size of approximately $200 million.

According to published terms, the shares filed represent a 100 percent primary offering. The company utilizes a differentiated approach to identify clinically validated mechanisms with established efficacy and safety profiles that were historically limited by high first-pass metabolism or low bioavailability. To overcome these limitations, Seaport Therapeutics applies its proprietary Glyph platform to invent innovative oral therapies. As reported in the preliminary terms, the IPO features Goldman Sachs, J.P. Morgan, Leerink, Citi, and Stifel as lead bookrunners, with J.P. Morgan acting as the stabilization agent.

Chaevi Co Ltd (Ticker: 0011T0 KS) is a South Korea-based company specializing in end-to-end electric vehicle (EV) charging solutions. The company designs, manufactures, and operates EV charging infrastructure, ranging from residential units to Asia’s first megawatt-scale charging stations. Chaevi currently manages over 10,000 fast-charging ports in South Korea and has expanded its footprint into the United States across 13 states.

Chaevi plans to list on the KOSDAQ exchange on April 30, 2026. The company is offering 10.00 million primary shares with an expected price range of KRW 12,300 to KRW 15,300. The IPO aims to raise approximately KRW 153.00 billion ($104.58 million USD). According to preliminary data, the company reportedly intends to use the proceeds to further its research and development initiatives, expand its manufacturing capabilities, and support its international business development, particularly in the North American and Asian markets. The offering is being managed by KB Securities and Samsung Securities. Since its founding in 2016, Chaevi has established partnerships with major automotive OEMs and public-sector entities, maintaining high technical standards including ISO 15118 and ENERGY STAR certifications.

Electrovac AG (Ticker: EVAC GR) is a German company specializing in hermetic glass-to-metal packaging for protecting safety- and mission-critical electronics. Electrovac AG plans to list on the Frankfurt Stock Exchange on April 30, 2026, planning to offer up to 4.76 million shares at an expected price range of EUR 7.80 to EUR 10.20, raising a base amount of EUR 42.23 million (USD 49.83 million). At the midpoint of the price range, the implied market capitalization is approximately EUR 144 million (USD 169.90 million).

According to the prospectus, the company is a fully integrated supplier with end-to-end manufacturing expertise, serving the personal safety, aerospace, and defense sectors with both customized solutions and high-volume series production.

As reported in the published terms, Electrovac plans to use the IPO proceeds primarily to accelerate the expansion of its international production capacity. The offering structure includes up to 3.84 million new shares from a cash capital increase, alongside secondary shares offered by the selling shareholder, Electrovac Holding AG. Reportedly, the underwriters managing the offering include B. Metzler seel. Sohn & Co. AG and BankM acting as joint global coordinators.

Hemab Therapeutics Holdings, Inc. (Ticker: COAG US) is an American clinical-stage biotech company focused on developing subcutaneous treatments for rare blood coagulation disorders. Hemab Therapeutics Holdings plans to list on the NASDAQ on May 1, 2026, planning to offer 11.76 million shares at a price range of $16.00 to $18.00, raising approximately $200 million at the midpoint of the range.

The Delaware-incorporated pharmaceutical company, founded in 2020, is developing its most advanced drug candidate, sutacimig, also known as HMB-001. The treatment has completed Phase 2 clinical trials and is reportedly ready to move into Phase 3 testing for Glanzmann thrombasthenia, a rare bleeding disorder. It is also in Phase 2 testing for Factor VII deficiency, another condition that affects the blood’s ability to clot. According to the prospectus, the company’s second drug candidate, HMB-002, is currently in Phase 1/2 trials for Von Willebrand Disease, a more common inherited bleeding disorder. The company does not yet generate revenue and reported a net loss of $63.91 million for the year ended December 31, 2025. Goldman Sachs, Jefferies, and Evercore ISI are serving as joint managers for the offering.

Star Sports Medicine Co Ltd (Ticker: 1609 HK) is a China-based medical device company specializing in clinical sports medicine solutions. Star Sports Medicine plans to list on the Hong Kong Stock Exchange on May 5, 2026, planning to offer 8.42 million shares at a price of HKD 98.50, raising HKD 829.55 million (USD 105.88 million). The company is expected to have a market capitalization of USD 689.37 million at the time of the IPO.

According to the prospectus, Star Sports Medicine plans to use the IPO proceeds for research and development, product capacity expansion, brand promotion, business development, working capital, and strategic acquisitions. As reported in the prospectus, the company offers holistic solutions for the treatment of injuries to soft tissues, including rotator cuffs, ligaments, and meniscus. Reportedly, it is the largest domestic sports medicine implants and instruments provider in China, holding an approximate 6.5% market share. The offering is structured as an H Share listing. CCB International Capital and CITIC Securities are serving as the joint sponsors for the deal, alongside other joint managers including CLSA, CMBC Securities, and China Galaxy International.